Delphine Collin
About Delphine Collin
Delphine Collin's Current Role
Delphine Collin serves as the Senior Vice President, Head of Drug Discovery at her current organization. In this role, she is responsible for overseeing the entire drug discovery process, from target identification to clinical candidate selection. Her work ensures the advancement of promising small molecule therapies through preclinical stages.
Delphine Collin's Education and Academic Background
Delphine Collin holds a Ph.D. in Physical Chemistry and a Pharm.D. from the University of Paris XI. Her strong educational foundation in both chemistry and pharmacy has equipped her with the expertise to lead high-impact drug discovery programs. This dual background provides her with a comprehensive understanding of both the scientific and clinical aspects required for effective drug development.
Delphine Collin's Experience in Small Molecule Drug Discovery
With over 20 years of experience in small molecule drug discovery and preclinical development, Delphine Collin has accumulated extensive expertise in the field. Her experience includes pioneering the use of label-free technologies at Merck & Co., leading early discovery activities at Cedilla Therapeutics, and overseeing external innovation at Faze Medicine. She has successfully managed programs from target identification to IND filing and beyond.
Delphine Collin's Contributions at Boehringer Ingelheim
While at Boehringer Ingelheim, Delphine Collin led small molecule programs that achieved critical stage-gate transitions, including Investigational New Drug (IND) filing. Her leadership in these programs was instrumental in progressing compounds from the laboratory to clinical development. This experience underlines her capability to drive projects through key regulatory milestones.
Delphine Collin's Career Beginnings at Merck & Co.
Delphine Collin began her career at Merck & Co., where she was a pioneer in utilizing label-free technologies for drug discovery. Her innovative approach in this area set the stage for future advancements and significantly contributed to the company's pipeline. This early experience laid a strong foundation for her subsequent accomplishments in the pharmaceutical industry.